IMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Immuneering Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$3.66+0.07 (+1.95%)
Close on Oct 19, 2026
- Market cap
- $236.79M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.92 (−34.41%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $236.79M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.24
- Dividend yield
- –
- Free cash flow yield
- -24.07%
Fundamentals
- Net income
- -$57.28M
- EPS, diluted
- -$1.04
- Free cash flow
- -$56.99M
- Book value per share
- $2.95
- Diluted shares
- 65M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
–
Gross profit
–
Operating income
-$63.47M
Net income
-$57.28M
EPS, diluted
-$1.04
Free cash flow
-$56.99M
Reported periodTrailing twelve months